Class 2 Medicines Recall: Sandimmun Oral Solution (Novartis Pharmaceuticals UK)
Drug alert number: EL(22)A/40
Date issued: 20 September 2022
The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a class 2 medicines recall for:
Sandimmun Oral Solution PL 00101/0124
Active Pharmaceutical Ingredient: ciclosporin
Brief description of the problem
Novartis Pharmaceuticals UK are recalling the above batch due to the presence of crystals in the solution. The crystals have been identified as the active substance (ciclosporin). The presence of crystals has been observed in some finished product packs marketed in other countries that share the same master batch as the UK batch above. Therefore, this UK batch is recalled as a precautionary measure. Novartis Pharmaceuticals UK have confirmed no other batches of the product are impacted.
Advice for healthcare professionals
Stop supplying the above batch immediately. Quarantine all remaining stock and return it to your supplier using your supplier’s approved process.
Full drug alert can be viewed here.
Advice for patients
Patients should not stop taking Sandimmun Oral Solution without speaking to your doctor or other healthcare professionals, as stopping your treatment may increase the risk of your transplanted organ being rejected.
The Marketing Authorisation Holder in the UK has not received any product complaints or adverse reactions related to the issue above. However, if you feel unwell whilst taking medicines from this batch then please seek urgent medical attention. Adverse reactions should also be reported via the MHRA Yellow Card scheme.
If you have any questions about your Sandimmun Oral Solution or observe crystallised particles in the solution, talk to your pharmacist, transplant team or other healthcare professionals for advice.
For more information, medical or supply enquiries, please contact 01276 698370, or email firstname.lastname@example.org
The post MHRA Class 2 Medicines Recall: Sandimmun Oral Solution Novartis Pharmaceuticals UK appeared first on PSNC Website.